Morgan Stanley’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.8M Sell
3,584,155
-264,912
-7% -$2.91M ﹤0.01% 2487
2025
Q4
$47.8M Buy
3,849,067
+24,404
+0.6% +$324K ﹤0.01% 2120
2025
Q3
$54.8M Sell
3,824,663
-109,347
-3% -$1.5M ﹤0.01% 1934
2025
Q2
$48.3M Sell
3,934,010
-876,770
-18% -$12.7M ﹤0.01% 1967
2025
Q1
$106M Sell
4,810,780
-510,463
-10% -$12M 0.01% 1211
2024
Q4
$121M Buy
5,321,243
+64,887
+1% +$1.42M 0.01% 1125
2024
Q3
$95.5M Sell
5,256,356
-242,171
-4% -$5.61M 0.01% 1276
2024
Q2
$160M Buy
5,498,527
+583,984
+12% +$17.3M 0.01% 901
2024
Q1
$174M Sell
4,914,543
-5,626,851
-53% -$225M 0.01% 868
2023
Q4
$459M Buy
10,541,394
+4,592,752
+77% +$181M 0.02% 710
2023
Q3
$227M Sell
5,948,642
-307,361
-5% -$12.9M 0.02% 643
2023
Q2
$257M Sell
6,256,003
-317,007
-5% -$15.3M 0.03% 619
2023
Q1
$377M Buy
6,573,010
+276,245
+4% +$15.6M 0.04% 448
2022
Q4
$353M Buy
6,296,765
+5,372,602
+581% +$273M 0.04% 460
2022
Q3
$39.1M Buy
924,163
+40,328
+5% +$2.07M 0.01% 1515
2022
Q2
$47.8M Buy
883,835
+161,612
+22% +$9.71M 0.01% 1401
2022
Q1
$46.4M Buy
722,223
+64,315
+10% +$4.23M 0.01% 1351
2021
Q4
$44.1M Sell
657,908
-75,960
-10% -$5.14M 0.01% 1435
2021
Q3
$50.3M Buy
733,868
+203,824
+38% +$14.4M 0.01% 1289
2021
Q2
$36.2M Buy
530,044
+73,317
+16% +$5.18M ﹤0.01% 1576
2021
Q1
$31.6M Sell
456,727
-18,102
-4% -$1.23M ﹤0.01% 1526
2020
Q4
$30.8M Buy
474,829
+79,336
+20% +$4.27M ﹤0.01% 1450
2020
Q3
$18.7M Buy
395,493
+12,060
+3% +$574K ﹤0.01% 1537
2020
Q2
$18M Buy
383,433
+6,652
+2% +$327K ﹤0.01% 1490
2020
Q1
$16.8M Buy
376,781
+252,381
+203% +$13.2M ﹤0.01% 1401
2019
Q4
$7.25M Buy
124,400
+20,698
+20% +$1.23M ﹤0.01% 2779
2019
Q3
$6.23M Buy
103,702
+76,400
+280% +$4.55M ﹤0.01% 2636
2019
Q2
$1.52M Sell
27,302
-4,644
-15% -$239K ﹤0.01% 3981
2019
Q1
$1.78M Sell
31,946
-194,831
-86% -$9.92M ﹤0.01% 3680
2018
Q4
$10.2M Buy
226,777
+132,753
+141% +$7.28M ﹤0.01% 2104
2018
Q3
$6.19M Sell
94,024
-63,011
-40% -$3.92M ﹤0.01% 2952
2018
Q2
$10.1M Sell
157,035
-8,742
-5% -$541K ﹤0.01% 2369
2018
Q1
$9.17M Buy
165,777
+5,123
+3% +$269K ﹤0.01% 2427
2017
Q4
$7.69M Buy
160,654
+49,866
+45% +$2.44M ﹤0.01% 2659
2017
Q3
$5.59M Buy
110,788
+31,561
+40% +$1.62M ﹤0.01% 2852
2017
Q2
$4.32M Sell
79,227
-265,271
-77% -$12.7M ﹤0.01% 3009
2017
Q1
$14.5M Buy
344,498
+143,826
+72% +$6.15M ﹤0.01% 1845
2016
Q4
$8.61M Buy
200,672
+21,258
+12% +$864K ﹤0.01% 2420
2016
Q3
$7.41M Buy
179,414
+141,846
+378% +$5.94M ﹤0.01% 2287
2016
Q2
$1.5M Sell
37,568
-138,206
-79% -$4.97M ﹤0.01% 3665
2016
Q1
$5.92M Buy
175,774
+139,682
+387% +$4.35M ﹤0.01% 2369
2015
Q4
$1.22M Buy
36,092
+7,940
+28% +$248K ﹤0.01% 3909
2015
Q3
$838K Sell
28,152
-62,385
-69% -$1.95M ﹤0.01% 4258
2015
Q2
$2.49M Buy
90,537
+38,001
+72% +$1.01M ﹤0.01% 3419
2015
Q1
$1.32M Sell
52,536
-2,116
-4% -$50K ﹤0.01% 3919
2014
Q4
$1.21M Buy
54,652
+10,527
+24% +$213K ﹤0.01% 3992
2014
Q3
$895K Sell
44,125
-10,598
-19% -$211K ﹤0.01% 4125
2014
Q2
$1.05M Sell
54,723
-10,101
-16% -$188K ﹤0.01% 4016
2014
Q1
$1.22M Buy
64,824
+41,306
+176% +$797K ﹤0.01% 3831
2013
Q4
$459K Sell
23,518
-2,322
-9% -$42.6K ﹤0.01% 4509
2013
Q3
$425K Sell
25,840
-7,403
-22% -$119K ﹤0.01% 4440
2013
Q2
$498K Buy
+33,243
New +$487K ﹤0.01% 4261

Other funds holding IART

Morgan Stanley's IART Position: Q1 2026 in Review

Morgan Stanley reduced its Integra LifeSciences (IART) stake by 6.9% in Q1 2026, selling an estimated $2.91M and leaving 3,584,155 shares worth $33.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Morgan Stanley first reported a position in IART in Q2 2013 and has held it in 52 quarters since. The position peaked at $459M in Q4 2023. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Morgan Stanley held 3,584,155 shares of Integra LifeSciences worth $33.8M as of Q1 2026.
  • Morgan Stanley sold 264,912 Integra LifeSciences shares in Q1 2026, an estimated $2.91M.
  • Integra LifeSciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2487 holding.
  • Morgan Stanley first reported a position in Integra LifeSciences in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Integra LifeSciences position peaked at $459M in Q4 2023.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.